Merck & Co., Inc. (LON:0QAH)

London flag London · Delayed Price · Currency is GBP · Price in USD
101.80
+1.15 (1.15%)
At close: Dec 19, 2025
1.60%
Market Cap187.61B
Revenue (ttm)47.79B
Net Income (ttm)14.16B
Shares Outn/a
EPS (ttm)5.62
PE Ratio13.25
Forward PE11.04
Dividend2.45 (2.41%)
Ex-Dividend DateDec 15, 2025
Volume9,921
Average Volume17,492
Open100.20
Previous Close100.64
Day's Range99.98 - 101.94
52-Week Range70.15 - 106.06
Beta0.30
RSI61.45
Earnings DateFeb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QAH
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.